<p>Yousif Capital Management LLC 在最近向证券交易委员会提交的 13F 文件中披露，在第二季度将其在赛诺菲（NASDAQ:SNY - 免费报告）的持股比例提高了 11.3%。该机构投资者在本季度额外购买了 6,789 股后，持有该公司 66,980 股股票。根据其最新的 SEC 文件，Yousif Capital Management LLC 在赛诺菲的持股价值为 3,236,000 美元。</p>
<ul>
<li>分析师们对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
<p>其他几家机构投资者也增加或减少了在 SNY 的持股。Ameritas Advisory Services LLC 在第二季度以 28,000 美元的估值购买了赛诺菲的新股份。Accent Capital Management LLC 在第一季度以 29,000 美元的估值购买了赛诺菲的新股份。Eastern Bank 在第一季度将其在赛诺菲的持股比例提高了 121.0%。Eastern Bank 现在拥有 548 股该公司的股票，价值 30,000 美元，此前在上个季度额外购买了 300 股。Banque Transatlantique SA 在第一季度以 33,000 美元的估值购买了赛诺菲的新股份。最后，Golden State Wealth Management LLC 在第一季度将其在赛诺菲的持股比例提高了 619.3%。Golden State Wealth Management LLC 现在拥有 633 股该公司的股票，价值 35,000 美元，此前在上个季度额外购买了 545 股。14.04% 的股票由机构投资者持有。</p>
<h2>分析师评级升级与降级</h2>
<p>几位股票研究分析师最近对 SNY 股票发表了评论。德意志银行股份公司在 9 月 2 日的研究报告中将赛诺菲的股票评级从 “持有” 上调至 “买入”。摩根大通在 8 月 8 日的研究报告中将赛诺菲的股票评级从 “中性” 上调至 “增持”。巴克莱在 7 月 2 日的研究报告中重申了对赛诺菲股票的 “增持” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对赛诺菲股票的 “持有（c）” 评级。最后，华尔街 Zen 在 8 月 2 日的研究报告中将赛诺菲的股票评级从 “持有” 上调至 “买入”。两位分析师给予该股票 “强烈买入” 评级，六位分析师给予 “买入” 评级，另外两位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价为 62.67 美元。</p>
<ul>
<li>分析师认为这些股票的价值可能会翻倍</li>
</ul>
<p><strong>查看我们关于 SNY 的最新报告</strong></p>
<h2>赛诺菲股票上涨 2.2%</h2>
<p>SNY 股票在周五开盘价为 50.02 美元。该公司的债务与股本比率为 0.19，速动比率为 0.94，流动比率为 1.27。该公司的 50 日移动平均线为 48.42 美元，200 日移动平均线为 49.65 美元。该股票的市值为 1,228.2 亿美元，市盈率为 12.02，PEG 比率为 1.19，贝塔值为 0.51。赛诺菲的 52 周低点为 44.62 美元，52 周高点为 60.12 美元。</p>
<ul>
<li>Regeneron：它是价值与增长的完美生物科技股票吗？</li>
</ul>
<p>赛诺菲（NASDAQ:SNY - 获取免费报告）最近在 7 月 31 日发布了其财报。该公司报告本季度每股收益（EPS）为 0.90 美元，低于分析师一致预期的 0.96 美元，差距为 0.06 美元。该公司本季度的收入为 113.4 亿美元，而一致预期为 99.1 亿美元。赛诺菲的净利润率为 21.47%，股本回报率为 16.86%。该公司本季度的收入较去年同期下降了 7.0%。在去年同期，该公司每股收益为 1.73 美元。卖方分析师预测，赛诺菲今年将发布 4.36 美元的每股收益。</p>
<h2>赛诺菲公司简介</h2>
<p>（免费报告）</p>
<p>赛诺菲是一家医疗保健公司，专注于在美国、欧洲、加拿大及国际市场的治疗解决方案的研究、开发、生产和营销。它通过制药、疫苗和消费者医疗保健三个部门运营。该公司提供特种护理，如 DUPIXENT、神经学和免疫学、罕见疾病、肿瘤学和罕见血液疾病；糖尿病和心血管疾病的药物；以及已建立的处方产品。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过赛诺菲</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>Salesforce 期待已久的转折点来了：继续上涨！</li>
<li>复利是如何计算的？</li>
<li>Rocket Lab USA 获得华尔街的认可：是时候买入了吗？</li>
<li>10 美元以下的最佳股票</li>
<li>Archer 以战略举措收购竞争对手的专利宝藏</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在赛诺菲吗？</h2>
<p>在你考虑赛诺菲之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而赛诺菲并不在名单上。</p>
<p>虽然赛诺菲目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

赛诺菲

<p>Yousif Capital Management LLC 在第二季度将其在赛诺菲（NASDAQ:SNY）的持股增加了 11.3%，额外购买了 6,789 股，总持股达到 66,980 股，价值 323.6 万美元。其他机构投资者也调整了他们在赛诺菲的持股。分析师们已上调了该股票的评级，平均目标价为 62.67 美元。赛诺菲的股票开盘价为 50.02 美元，市值为 1,228.2 亿美元。该公司报告第二季度每股收益为 0.90 美元，低于预期，营收为 113.4 亿美元，同比下降 7%</p>

<p>Yousif Capital Management LLC boosted its stake in Sanofi (NASDAQ:SNY - Free Report) by 11.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 66,980 shares of the company's stock after acquiring an additional 6,789 shares during the quarter. Yousif Capital Management LLC's holdings in Sanofi were worth $3,236,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Yousif Capital Management LLC 在最近向证券交易委员会提交的 13F 文件中披露，在第二季度将其在赛诺菲（NASDAQ:SNY - 免费报告）的持股比例提高了 11.3%。该机构投资者在本季度额外购买了 6,789 股后，持有该公司 66,980 股股票。根据其最新的 SEC 文件，Yousif Capital Management LLC 在赛诺菲的持股价值为 3,236,000 美元。</p>
</div><ul>
<li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师们对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
</div><p>Several other institutional investors have also added to or reduced their stakes in SNY. Ameritas Advisory Services LLC bought a new stake in Sanofi in the 2nd quarter valued at $28,000. Accent Capital Management LLC bought a new stake in Sanofi in the 1st quarter valued at $29,000. Eastern Bank lifted its position in Sanofi by 121.0% in the 1st quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after acquiring an additional 300 shares in the last quarter. Banque Transatlantique SA bought a new stake in Sanofi in the 1st quarter valued at $33,000. Finally, Golden State Wealth Management LLC lifted its position in Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after acquiring an additional 545 shares in the last quarter. 14.04% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者也增加或减少了在 SNY 的持股。Ameritas Advisory Services LLC 在第二季度以 28,000 美元的估值购买了赛诺菲的新股份。Accent Capital Management LLC 在第一季度以 29,000 美元的估值购买了赛诺菲的新股份。Eastern Bank 在第一季度将其在赛诺菲的持股比例提高了 121.0%。Eastern Bank 现在拥有 548 股该公司的股票，价值 30,000 美元，此前在上个季度额外购买了 300 股。Banque Transatlantique SA 在第一季度以 33,000 美元的估值购买了赛诺菲的新股份。最后，Golden State Wealth Management LLC 在第一季度将其在赛诺菲的持股比例提高了 619.3%。Golden State Wealth Management LLC 现在拥有 633 股该公司的股票，价值 35,000 美元，此前在上个季度额外购买了 545 股。14.04% 的股票由机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级升级与降级</h2>
</div><p>Several equities research analysts recently commented on SNY shares. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Tuesday, September 2nd. JPMorgan Chase &amp; Co. raised shares of Sanofi from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating in a research report on Friday, August 8th. Barclays reissued an &#34;overweight&#34; rating on shares of Sanofi in a research report on Wednesday, July 2nd. Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Sanofi in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Sanofi from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, August 2nd. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Buy&#34; and an average target price of $62.67.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对 SNY 股票发表了评论。德意志银行股份公司在 9 月 2 日的研究报告中将赛诺菲的股票评级从 “持有” 上调至 “买入”。摩根大通在 8 月 8 日的研究报告中将赛诺菲的股票评级从 “中性” 上调至 “增持”。巴克莱在 7 月 2 日的研究报告中重申了对赛诺菲股票的 “增持” 评级。Weiss Ratings 在 10 月 8 日的研究报告中重申了对赛诺菲股票的 “持有（c）” 评级。最后，华尔街 Zen 在 8 月 2 日的研究报告中将赛诺菲的股票评级从 “持有” 上调至 “买入”。两位分析师给予该股票 “强烈买入” 评级，六位分析师给予 “买入” 评级，另外两位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价为 62.67 美元。</p>
</div><ul>
<li>Analysts Think These Stocks Could More Than Double in Value</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师认为这些股票的价值可能会翻倍</li>
</ul>
</div><p><strong>View Our Latest Report on SNY</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 SNY 的最新报告</strong></p>
</div><h2>Sanofi Stock Up 2.2%</h2>
<div class="lb-trans"><h2>赛诺菲股票上涨 2.2%</h2>
</div><p>Shares of SNY stock opened at $50.02 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The firm's 50-day moving average is $48.42 and its 200-day moving average is $49.65. The stock has a market cap of $122.82 billion, a price-to-earnings ratio of 12.02, a PEG ratio of 1.19 and a beta of 0.51. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12.</p>
<div class="lb-trans"><p>SNY 股票在周五开盘价为 50.02 美元。该公司的债务与股本比率为 0.19，速动比率为 0.94，流动比率为 1.27。该公司的 50 日移动平均线为 48.42 美元，200 日移动平均线为 49.65 美元。该股票的市值为 1,228.2 亿美元，市盈率为 12.02，PEG 比率为 1.19，贝塔值为 0.51。赛诺菲的 52 周低点为 44.62 美元，52 周高点为 60.12 美元。</p>
</div><ul>
<li>Regeneron: Is It the Perfect Biotech Stock for Value and Growth?</li>
</ul>
<div class="lb-trans"><ul>
<li>Regeneron：它是价值与增长的完美生物科技股票吗？</li>
</ul>
</div><p>Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The firm had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm's revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.73 earnings per share. Sell-side analysts predict that Sanofi will post 4.36 EPS for the current year.</p>
<div class="lb-trans"><p>赛诺菲（NASDAQ:SNY - 获取免费报告）最近在 7 月 31 日发布了其财报。该公司报告本季度每股收益（EPS）为 0.90 美元，低于分析师一致预期的 0.96 美元，差距为 0.06 美元。该公司本季度的收入为 113.4 亿美元，而一致预期为 99.1 亿美元。赛诺菲的净利润率为 21.47%，股本回报率为 16.86%。该公司本季度的收入较去年同期下降了 7.0%。在去年同期，该公司每股收益为 1.73 美元。卖方分析师预测，赛诺菲今年将发布 4.36 美元的每股收益。</p>
</div><h2>Sanofi Company Profile</h2>
<div class="lb-trans"><h2>赛诺菲公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.</p>
<div class="lb-trans"><p>赛诺菲是一家医疗保健公司，专注于在美国、欧洲、加拿大及国际市场的治疗解决方案的研究、开发、生产和营销。它通过制药、疫苗和消费者医疗保健三个部门运营。该公司提供特种护理，如 DUPIXENT、神经学和免疫学、罕见疾病、肿瘤学和罕见血液疾病；糖尿病和心血管疾病的药物；以及已建立的处方产品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Sanofi</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Salesforce’s Long-Awaited Inflection is Here: Rally On!</li>
<li>How is Compound Interest Calculated?</li>
<li>Rocket Lab USA Receives Wall Street Validation: Time to Buy?</li>
<li>Best Stocks Under $10.00</li>
<li>Archer Buys Rival's Patent Treasure Trove in Strategic Move</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过赛诺菲</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>Salesforce 期待已久的转折点来了：继续上涨！</li>
<li>复利是如何计算的？</li>
<li>Rocket Lab USA 获得华尔街的认可：是时候买入了吗？</li>
<li>10 美元以下的最佳股票</li>
<li>Archer 以战略举措收购竞争对手的专利宝藏</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SNY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sanofi Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在赛诺菲吗？</h2>
</div><p>Before you consider Sanofi, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑赛诺菲之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而赛诺菲并不在名单上。</p>
</div><p>While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然赛诺菲目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Yousif Capital Management LLC 购买了 6,789 股赛诺菲股票，代码为$SNY